 Akebia Therapeutics NASDAQ:AKBA was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Monday, Zacks.com reports. The firm presently has a 13.00 price target on the biopharmaceutical companys stock. Zacks Investment Researchs price objective indicates a potential upside of 3.67 from the companys current ... 